These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21930862)

  • 61. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection.
    Nishijima T; Shimbo T; Komatsu H; Hamada Y; Gatanaga H; Kikuchi Y; Oka S
    J Antimicrob Chemother; 2014 May; 69(5):1385-9. PubMed ID: 24379301
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interaction between antiretroviral drugs and acenocoumarol.
    Welzen ME; van den Berk GE; Hamers RL; Burger DM
    Antivir Ther; 2011; 16(2):249-52. PubMed ID: 21447874
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():24-5. PubMed ID: 25026852
    [No Abstract]   [Full Text] [Related]  

  • 66. Initial treatment of HIV-1 infection.
    Schulz TR; Street AC
    N Engl J Med; 2008 Aug; 359(9):970; author reply 971. PubMed ID: 18753656
    [No Abstract]   [Full Text] [Related]  

  • 67. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Initial treatment for HIV infection--an embarrassment of riches.
    Hirschel B; Calmy A
    N Engl J Med; 2008 May; 358(20):2170-2. PubMed ID: 18480210
    [No Abstract]   [Full Text] [Related]  

  • 69. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Report from the 13th retrovirus conference. Extending the role of atazanavir.
    Feinberg J
    AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
    [No Abstract]   [Full Text] [Related]  

  • 72. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):80. PubMed ID: 20458811
    [No Abstract]   [Full Text] [Related]  

  • 73. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
    Pillai VC; Venkataramanan R; Parise RA; Christner SM; Gramignoli R; Strom SC; Rudek MA; Beumer JH
    Drug Metab Dispos; 2013 Oct; 41(10):1843-51. PubMed ID: 23913028
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.
    Haerter G; Manfras BJ; Mueller M; Kern P; Trein A
    AIDS; 2004 Apr; 18(6):952-5. PubMed ID: 15060446
    [No Abstract]   [Full Text] [Related]  

  • 75. Protease inhibitors show promise in HIV infection.
    Nelson H
    Lancet; 1996 Feb; 347(8998):383. PubMed ID: 8598709
    [No Abstract]   [Full Text] [Related]  

  • 76. Medication-based urolithiasis and atazanavir.
    Koblic PM; Gold WL; la Porte CJ; Lee TC
    CMAJ; 2011 Aug; 183(11):E748-51. PubMed ID: 21444613
    [No Abstract]   [Full Text] [Related]  

  • 77. Report from the 16th Conference on Retroviruses and Opportunistic Infections. Investigational pharmacologic boosters.
    Hicks CB
    J Watch AIDS Clin Care; 2009 Apr; 21(4):33-4. PubMed ID: 19548333
    [No Abstract]   [Full Text] [Related]  

  • 78. CROI round-up. New information on the heart, plus a possible alternative to Norvir and more.
    Posit Aware; 2009; 20(3):30-1. PubMed ID: 19492446
    [No Abstract]   [Full Text] [Related]  

  • 79. Call to rescind price boosting of ritonavir.
    Quirk M
    Lancet Infect Dis; 2004 Feb; 4(2):68. PubMed ID: 14959760
    [No Abstract]   [Full Text] [Related]  

  • 80. Frequency of atazanavir-associated leukocyturia development and renal function decline.
    Dbeibo L; Arif S; He F; Gupta SK
    AIDS; 2016 Jun; 30(9):1488-9. PubMed ID: 27167012
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.